Jun. 26 at 9:45 PM
This setup on
$ZTS looks like a classic long-term accumulation thesis, but the range and target need to be grounded in reality.
Buy zone:
$47.27–
$76.80 suggests a deep value or long-cycle entry, and starting a position here implies patience through volatility.
Long-term PT:
$440 implies a multi-year re-rating driven by earnings compounding + margin expansion + defensive pharma/animal health premium revaluation.
Key thesis would need to hold:
Sustained revenue growth in animal health demand
Pricing power + margin recovery
Consistent cash flow expansion over cycles
Risk is that
$ZTS typically behaves as a steady compounder, not a high-beta rerating story, so hitting
$440 would require a strong structural multiple expansion, not just earnings growth.
